{
    "pmcid": "11140877",
    "summary": "The paper titled \"Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses\" provides a comprehensive review of the development and application of nanobodies as therapeutic agents targeting SARS-CoV-2 and other pathogenic coronaviruses. Here is a detailed summary focusing on the key insights related to nanobodies and their design for SARS-CoV-2:\n\n### Nanobodies Overview\n- **Definition and Origin**: Nanobodies are single-domain antibodies derived from the variable domain of camelid or shark heavy-chain antibodies. They are characterized by their small size (~15 kDa), strong binding affinity, and ability to penetrate tissues effectively.\n- **Advantages**: Nanobodies offer several benefits over conventional antibodies, including high solubility, stability, resistance to extreme conditions, and low immunogenicity in humans. They can be easily humanized to further reduce immunogenicity.\n- **Formats and Engineering**: Nanobodies can be engineered into multivalent formats (dimeric, trimeric) to enhance their avidity and neutralizing efficiency. They can also be fused with other proteins, such as the Fc region of human IgG, to increase their serum half-life and manufacturability.\n\n### Targeting SARS-CoV-2\n- **Spike Protein as a Target**: The spike (S) protein of SARS-CoV-2, particularly its receptor-binding domain (RBD), is a primary target for nanobody development due to its critical role in viral entry and pathogenesis.\n- **RBD-Targeting Nanobodies**: Most nanobodies developed against SARS-CoV-2 target the RBD, aiming to block the interaction with the ACE2 receptor. These nanobodies can be categorized based on their binding sites: those that compete with ACE2 and those that bind to conserved epitopes outside the ACE2-binding site.\n- **Neutralizing Activity**: RBD-targeting nanobodies have demonstrated varying degrees of neutralizing activity against the original SARS-CoV-2 strain and its variants, including Omicron subvariants. Some nanobodies maintain binding to conserved RBD epitopes, which helps retain their efficacy against multiple variants.\n- **Structural Insights**: Crystal and cryo-EM structures of nanobody-RBD complexes have been solved, providing insights into the binding mechanisms and guiding the rational design of more effective nanobodies.\n\n### Cross-Reactivity and Broad Neutralization\n- **Cross-Reactive Nanobodies**: Some nanobodies exhibit cross-reactivity with the RBDs of SARS-CoV and SARS-CoV-2, and even with other sarbecoviruses. These nanobodies target conserved epitopes, offering potential for broad-spectrum antiviral activity.\n- **Challenges and Strategies**: The continuous mutation of the SARS-CoV-2 RBD necessitates the development of new nanobodies with broad and potent neutralizing activity. Structure-guided design and molecular modeling are crucial for rapidly developing nanobodies against emerging variants.\n\n### Therapeutic Applications and Delivery\n- **Animal Models and Clinical Trials**: Several nanobodies have shown protective efficacy in animal models, such as mice and hamsters, and some have progressed to human clinical trials. Delivery methods include intraperitoneal, aerosol, and intranasal routes.\n- **Combination Therapies**: Combining nanobodies with other therapeutic agents, such as monoclonal antibodies or antiviral drugs, may enhance their prophylactic and therapeutic efficacy.\n\n### Future Directions\n- **Universal Nanobodies**: The S2 region of the spike protein, which is more conserved across CoV strains, is a promising target for developing universal nanobodies with broad-spectrum activity.\n- **Multivalent and Combinatorial Approaches**: Constructing multivalent nanobodies or using combinatorial therapies could improve efficacy against diverse CoV variants.\n- **Clinical Development**: Despite the promising potential of nanobodies, more funding and research are needed to advance these candidates into clinical studies and eventual approval for human use.\n\nOverall, the review highlights the potential of nanobodies as versatile and effective therapeutic agents against SARS-CoV-2 and other pathogenic coronaviruses. It emphasizes the importance of continued research and development to address the challenges posed by emerging variants and to harness the full potential of nanobodies in combating viral infections.",
    "title": "Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses"
}